

## Rheumatoid arthritis (update) Committee meeting 7

**Date:** 30/05/2017

**Location:** Boardroom, NGC, 180 Great Portland Street, London, W1W 5QZ

**Minutes:** Confirmed

**NICE** National Institute for  
Health and Care Excellence

<b>Committee members present:</b>	
Stephen Ward (SW, Chair)	(Present for notes 1–5)
Ann Bevan (ABe)	(Present for notes 1–5)
Ailsa Bosworth (ABo)	(Present for notes 1–5)
Jennie Jones (JJ)	(Present for notes 1–5)
Bruce Kirkham (BK)	(Present for notes 1–5)
Hilary McKee (HMK)	(Present for notes 1–5)
Frank McKenna (FMK)	(Present for notes 1–5)
Anupama Nandagudi (AN, via WebEx)	(Present for notes 1–5)
Benjamin Parker (BPa)	(Present for notes 1–5)
Heidi Siddle	(Present for notes 1–5)
Louise Warburton (LW)	(Present for notes 1–5)

<b>In attendance:</b>		
Anne-Louise Clayton	Editor, NICE	(Present for notes 4B–5)
Caroline Keir	Guideline Commissioning Manager, NICE	(Present for notes 4A–5)
Alex Allen	Senior Research Fellow, NGC	(Present for notes 1–5)
Serena Carville	Guideline Lead/Associate Director, NGC	(Present for notes 1–5)
Meredith Faust	Document Editor/Process Assistant, NGC	(Present for notes 1–4B)
Sophia Kemmis-Betty	Senior Health Economist, NGC	(Present for notes 1–5)
Ben Pordes	Senior Project Manager, NGC	(Present for notes 4B–5)

Jacqui Real	Senior Research Fellow, NGC	(Present for notes 1–5)
Grit Scheffler-Ansari	Research Fellow, NGC	(Present for notes 1–5)

**Apologies:**

Vicky Chamberlain (VC)	Rheumatology Nurse Specialist
Lina Gulhane (LG)	Senior Information Scientist, NGC

**1. Welcome and objectives for the meeting**

The Chair welcomed the committee members and attendees to the seventh meeting on rheumatoid arthritis. The committee members and attendees introduced themselves.

No members of the public asked to observe the meeting.

The Chair informed the committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included: first- and second-line DMARDs.

**2. Confirmation of matter under discussion, and declarations of interest**

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was DMARDs.

The Chair asked everyone to declare verbally any interests that have arisen since the last meeting.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Bruce Kirkham	Consultant Rheumatologist, Guy's and St Thomas' NHS Foundation Trust	Targeted Therapies meeting, Nice, France 27–30 March, Funded by Universities of Vienna, Leiden and Erlangen supported by non-directed educational	Non-personal, financial, non-specific	Declare and participate

		grants from pharmaceutical companies, including Abbvie, Astra-Zenaca, Chugai, Lilly, Nippon Pharma, and Pfizer. I received travel and hotel accommodation; Honorarium is paid to Guy's & St Thomas' NHS Foundation Trust.		
		Participant in Novartis sponsored debate on Psoriatic Arthritis, Wed 26 April at the British Society of Rheumatology conference – I receive travel and hotel accommodation, Honorarium is paid to Guys & St Thomas NHS Foundation Trust	Non-personal, financial, non-specific	Declare and participate

The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

### 3. Minutes of last meeting

The Chair asked the committee if it wanted any changes made to the minutes of the last meeting. The committee agreed that the minutes were a true and accurate account of the meeting.

The Chair confirmed that all matters arising had been completed or were in hand.

#### 4. Presentations and discussion

- A. JR presented the data for the following review question: In adults with RA who are DMARD naïve, which conventional DMARDs (alone or combined) are most clinically and cost effective?
- i. AA presented the clinical outcomes of the evidence reviewed.
  - ii. SKB presented the health economic evidence related to the above review question.
  - iii. The committee drafted recommendations based on the evidence.
- B. GSA presented the data for the following review question: In adults with RA who have had an inadequate response to, or failed treatment with, one or more conventional DMARDs, which conventional DMARDs (alone or combined) are most clinically and cost effective as subsequent treatments?
- i. The committee drafted recommendations based on the evidence.
- C. JR presented the drafted linking evidence to recommendations documents for the question: *In adults with suspected inflammatory arthritis (including rheumatoid arthritis), what is the added value of ultrasound in the diagnosis of rheumatoid arthritis?* The committee made amendments.
- D. JR presented the drafted linking evidence to recommendations documents for the question: *In adults with rheumatoid arthritis, what is the added value of monitoring disease activity with ultrasound?* The committee made amendments.

#### 5. Any other business

None.

**Date of next meeting:** 05/07/2017

**Location of next meeting:** National Guideline Centre, 180 Great Portland Street,  
London W1W 5QZ